Cytosolic group IVa phospholipase A2 mediates IL-8/CXCL8-induced transmigration of human polymorphonuclear leukocytes in vitro by Meliton, Angelo Y et al.
Meliton et al. Journal of Inflammation 2010, 7:14
http://www.journal-inflammation.com/content/7/1/14
Open Access RESEARCH
© 2010 Meliton et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research Cytosolic group IVa phospholipase A2 mediates 
IL-8/CXCL8-induced transmigration of human 
polymorphonuclear leukocytes in vitro
Angelo Y Meliton1, Nilda M Muñoz*1, Lucille N Meliton1, David C Binder1, Christopher M Osan1, Xiangdong Zhu1, 
Steven M Dudek1 and Alan R Leff1,2
Abstract
Background: Cytosolic gIVaPLA2 is a critical enzyme in the generation of arachidonate metabolites and in induction of 
β2-integrin adhesion in granulocytes. We hypothesized that gIVaPLA2 activation also is an essential downstream step 
for post adhesive migration of PMN in vitro.
Methods: Migration of PMNs caused by IL-8/CXCL8 was assessed using a transwell migration chamber. PMNs were 
pretreated with two structurally unrelated inhibitors of gIVaPLA2, arachidonyl trifluoromethylketone (TFMK) or 
pyrrophenone, prior to IL-8/CXCL8 exposure. The fraction of migrated PMNs present in the lower chamber was 
measured as total myeloperoxidase content. GIVaPLA2 enzyme activity was analyzed using [14C-PAPC] as specific 
substrate F-actin polymerization and cell structure were examined after rhodamine-phalloidin staining.
Results: IL-8/CXCL8-induced migration of PMNs was elicited in concentration- and time-dependent manner. Time-
related phosphorylation and translocation of cytosolic gIVaPLA2 to the nucleus was observed for PMNs stimulated with 
IL-8/CXCL8 in concentration sufficient to cause upstream phosphorylation of MAPKs (ERK-1/2 and p38) and Akt/PKB. 
Inhibition of gIVaPLA2 corresponded to the magnitude of blockade of PMN migration. Neither AA nor LTB4 secretion 
was elicited following IL-8/CXCL8 activation. In unstimulated PMNs, F-actin was located diffusely in the cytosol; 
however, a clear polarized morphology with F-actin-rich ruffles around the edges of the cell was observed after 
activation with IL-8/CXCL8. Inhibition of gIVaPLA2 blocked change in cell shape and migration caused by IL-8/CXCL8 
but did not cause F-actin polymerization or translocation of cytosolic F-actin to inner leaflet of the PMN membrane.
Conclusion: We demonstrate that IL-8/CXCL8 causes a) phosphorylation and translocation of cytosolic gIVaPLA2 to the 
nucleus, b) change in cell shape, c) polymerization of F-actin, and d) chemoattractant/migration of PMN in vitro. 
Inhibition of gIVaPLA2 blocks the deformability and subsequent migration of PMNs caused by IL-8/CXCL8. Our data 
suggest that activation of gIVaPLA2 is an essential step in PMN migration in vitro.
Background
IL-8/CXCL8 is a selective and potent neutrophil
chemoattractant. Previous studies have shown that
upstream activation of PI3K, ERK-1/2, or p38 MAPK [1-
7] pathways caused by IL-8/CXCL8 regulates the induc-
tion of transendothelial PMN migration. However, the
signaling mechanism downstream of these kinases in
causing migration of PMNs has not been established pre-
viously and critical intermediate steps regulating neutro-
phil migration remain unknown.
Phospholipase A2s (PLA2) are esterases that cleave
glycerophospholipids at the sn-2 ester bond, releasing a
fatty acid and a lysophospholipid [8-11]. PLA2s are
divided into five different groups; a) secretory PLA2
[12,13], b) cytosolic gIVPLA2 (gIVPLA2) [14], c) Ca2+-
independent PLA2, [15,16] d) platelet-activating factor
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hydrolyses, [17,18] and e) lysosomal PLA2 [19]. Among
these groups, gIVaPLA2 is thought to be not only a rate-
limiting enzyme in eicosanoid biosynthesis [20] but also
to be essential in maintenance of β2-integrin adhesion in
granulocytes [21,22]. We have shown previously that
ERK-1/2 and Akt/PKB phosphorylation activated
gIVaPLA2 to cause β2-integrin adhesion of granulocytes
to ICAM-1[23]. We also have shown that phosphoryla-
tion to activate gIVaPLA2 results from upstream phos-
phorylation of these kinase and that maintenance of this
phosphorylated state regulates the process of β2-integrin
adhesion [24,25].
Because MAP kinase and PI3K also regulate gIVaPLA2
phosphorylation, we postulated that activation of
gIVaPLA2  might regulate neutrophil migration. The
objective of this study was to examine specifically the
functional role of gIVaPLA2 in PMN migration caused by
IL-8/CXCL8. IL-8/CXCL8 was applied in concentration
causing upstream phosphorylation of ERK-1/2, p38
MAPK and Akt/PKB. We found that inhibition of
gIVaPLA2 activity blocked substantially the transmigra-
t i o n  t o w a r d  I L - 8 / C X C L 8  i n  a  t r a n s w e l l  c h a m b e r .  T h i s
study is the first demonstration that activation of
gIVaPLA2  is a critical regulatory step subsequent to
upstream activation of signaling kinases in eliciting PMN
migration.
Methods
Antibodies and reagents
IL-8/CXCL8 was purchased from Peprotech (Rocky Hill,
NJ) while bovine serum albumin fraction V and human
polymophonuclear leukocytes (PMNs) isolation materials
were purchased from Sigma-Aldrich Chemical Co. (St.
Louis, MO). Anti-phosphorylated gIVaPLA2 Ab (Ser505)
was purchased from Cell Signaling Technology (Beverly,
MA). Mouse IgG was purchased from BD Biosciences
(Mountain View, CA). Polystyrene 96-well microtiter
plates were obtained from Neuro Probe (Gaithersburg,
MD). Rhodamine-phalloidin was obtained from Sigma-
Aldrich Chemical (St. Louis, MO).
Isolation of human PMNs
Venous blood from normal human subjects (20-45 years
old) was collected in heparin-containing tubes, and
P M N s  w e r e  i s o l a t e d  b y  F i c o l l - P a q u e  s e d i m e n t a t i o n  a s
described previously [26,27]. Purity of PMN on H and E-
stained cytoslides was ~90-95%. Informed written con-
sent was obtained from all volunteers in this study.
Transwell migration assay
PMN migration in transwell microplates was assessed
using the standard methods as described previously [28].
Preliminary experiments have established that the num-
ber of cells (4 × 104 cells) used allow the optimal % cell
migration without clogging the pores of transwell filter of
the upper chamber. Cells then were preincubated with
HBSS, 3 μM - 30 μM arachidonyl trifluoromethylketone
[TFMK; inhibitor of gIVaPLA2 [29], or 10-9 M -10-6 M
pyrrophenone [inhibitor of gIVaPLA2 [30] for 30 min at
37°C. Treated cells in 50 μl HBSS were transferred onto 5
μm-pore transwell filters positioned on top of the migra-
tion chamber. HBSS or 10 ng/ml to 1000 ng/ml IL-8/
CXCL8 was loaded in the bottom chamber (final volume
= 310 μl), and the transwell microplates were incubated
for 60 min and 90 min at 37°C. The migrated PMNs were
treated with 100 μl of HBSS + 10% FBS buffer and 100 μl
developing solution [8 ml 100 nM NaH2PO4 (pH = 5.5),
1000 μl 10% hexadecyltrimethylammonium bromide
(HTAB), 3 μl 30% hydrogen peroxide, 1000 μl 10% o-dian-
isidine dihydrochloride]. The reaction was terminated by
addition of 50 μl sulfuric acid and myeloperoxidase
(MPO) activity was measured at 405 nm in a Thermomax
microplate reader (Molecular Devices, Menlo Park, CA).
T h e  f r a c t i o n  o f  m i g r a t e d  P M N s  p r e s e n t  i n  t h e  l o w e r
chamber was measured as total MPO content. Data were
expressed as % cell migration. Maximal, no-toxic inhibi-
tory concentration of TFMK and pyrrophenone were
established in initial studies demonstrating blockade of
gIVaPLA2 activity [see also Results].
In separate studies, morphological changes of the non-
migrated cells (top chamber) and migrated cells (bottom
chamber) toward IL-8/CXCL8 were examined. The effect
of 30 μM TFMK or 10-6 M pyrrophenone on cell deform-
ability caused by IL-8/CXCL8 also was examined using
confocal microscopy.
Immunoblotting analysis
PMNs (106 cells/group) were activated with HBSS and
100 ng/ml IL-8/CXCL8 at different time intervals, and
phosphorylation of ERK-1/2, p38 MAPK, and Akt/PKB
were analyzed using Western blot. The pellet was lysed in
disruption buffer (20 mM Tris-HCl, 30 mM Na4P2O7, 50
mM NaF, 40 mM NaCl, 5 mM EDTA, pH 7.4) containing
1% Nonidet P-40, 10 μg/ml leupeptin, 5 μg/ml aprotinin,
1 mM PMSF, 2 mM Na3VO4, and 0.5% deoxycholic acid.
Samples were loaded to SDS-PAGE using 8% (gIVaPLA2)
or 10% (ERK-1/2, p38 MAPK, PI3K) acrylamide gels
under reducing conditions. The membrane was blocked
with 1% BSA in TBS-T buffer and phosphorylated Ab
against ERK-1/2 (1:1000; Cell Signaling Technology; Bev-
erly, MA), p38 MAPK and Akt/PKB (1:1000; Cell Signal-
ing Technology; Beverly, MA), or Ser505  gIVaPLA2
(1:1000) was added followed by relevant secondary Ab
conjugated with HRP. Protein of interest was analyzed by
an enhanced chemiluminescence system (Amersham,
Arlington Heights, IL).Meliton et al. Journal of Inflammation 2010, 7:14
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Measurement of arachidonic acid (AA) release
Isolated PMNs were incubated in RPMI medium contain-
ing 5% FBS and 0.5 μCi [3H]AA. Labeled PMNs were
incubated for 2 h and unincorporated [3H]AA was
washed away by HBSS containing 0.2% BSA. Thereafter,
treated PMNs were activated with saline, 100 ng/ml IL-8/
CXCL8 or 1 μM FMLP (+ 5 μg/ml cytochalasin B). The
reaction was terminated by centrifugation at 12,000 × g
for 1 min. Supernatant were collected, and pellets were
lysed in 1% Triton X-100. [3H]AA release was measured
by scintillation counting and expressed as counts per min
(cpm) [21,24].
Measurement of LTB4 secretion
Aliquots of 250,000 were activated with saline, 1-1000 ng/
ml IL-8/CXCL8, or 1 μM FMLP (+ 5 μg/ml cytochalasin
B) for 15 min at 37°C in a final volume of 250 μl HBSS.
The reaction was terminated by centrifugation at 12,000
× g for 1 min. Aliquots of supernatants were assayed with
a commercial EIA kit as previously described [24,31].
GIVaPLA2 activity assay
GIVaPLA2 activity assay was determined in aliquots of 2
× 106 cells incubated for 15 min at 37°C with 3 μM - 30
μM TFMK or 10 -10 M - 10-6 M pyrrophenone. Activity
was measured at optimal time (30 min) after 100 ng/ml
IL-8/CXCL8 [see Results]. This time and concentration
were shown in initial studies to cause phosphorylation of
gIVaPLA2 in PMNs. The cell pellets were resuspended in
disruption buffer (see above) and immediately sonicated
followed by addition of specific substrate ([14C]-PAPC)
for gIVaPLA2[24,31]. To measure precisely the total
gIVaPLA2 activity, 5 mM dithiotrietol was added to cell
lysate to inactivate, if any, the remaining 10-14 kDa secre-
tory PLA2 enzymes that could interfere with the assay.
Thirty min later, the reaction was terminated by adding
560 μl of Dole's reagent (heptane:isopropyl alcohol:1 N
H2SO4; 400:390:10 by vol), and the radioactivity was mea-
sured in a liquid scintillation counter and expressed as
picomoles/30 min/106 cells [31].
Subfractionation
F r e s h l y  i s o l a t e d  P M N s  w e r e  p r e i n c u b a t e d  w i t h  e i t h e r
saline, 100 ng/ml IL-8/CXCL8, or 10-6 M FMLP for 15
min at 37°C. After washing with PBS, treated cells were
centrifuged for 1 min at 400 × g. The pellet were lysed in
50 μl disruption buffer (see above) and put on ice for 10
min. The disrupted pellets, which are mainly nuclear
component of the cells, were centrifuged at 500 × g for 1
min. A total of 50 μl of boiling buffer was added to the
pellets and boiled for 5 min. The supernatants were cen-
trifuged again at 100,000 × g for 1 h. Eight μl of loading
buffer was added to the collected supernatant, which is
the cytoplasm fraction, and was boiled for 5 min. Samples
were loaded onto SDS-PAGE and membrane was probed
with pAb against cPLA2. The translocation of cytosolic
gIVaPLA2  to the nuclear component of the cells was
d e t e c t e d  b y  a n  e n h a n c e d  c h e m i l u m i n e s c e n c e  ( A m e r -
sham, Arlington Heights, IL).
Change in cell shape and F-actin polymerization
Change in cell shape and F-actin polymerization were
examined in migrated cells. HBSS or rhodamine-phalloi-
din [32] was added to the paraformadehyde-fixed
cytoslides containing samples and changes in cell shape
and F-actin polymerization were analyzed by confocal
microscopy.
Statistical analysis
Experimental data are expressed as mean ± SEM in each
group. Student's t-test was used for comparison between
two-paired groups. Where multiple comparisons were
made, differences on concentration-response curves for
the same agonist or inhibitor were compared after Bonf-
eronni correction. Variation between more than two
groups was tested using one-way ANOVA followed by
Fisher' least protected difference test. Statistical signifi-
cance was claimed when P < 0.05.
Results
IL-8/CXCL8-induced migration
Migration of PMNs toward the IL-8/CXCL8 chamber
increased in time- and concentration-dependent manner
(Figure 1). Transmigration caused by 100 ng/ml IL-8/
CXCL8 was substantially greater after 90 min incubation
time compared to 60 min incubation time. PMN migra-
tion across the transwell filter in the absence of IL-8/
Figure 1 IL-8/CXCL8-induced neutrophil (PMN) migration. The 
concentration-response curve to IL-8/CXCL8-induced PMN migration 
was generated at 60 min or 90 min, and migration was assessed by 
measuring total myeloperoxidase activity in the neutrophil fraction 
(see Methods section). Data are expressed as % cell migration from N 
= 5 isolations.Meliton et al. Journal of Inflammation 2010, 7:14
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CXCL8 was < 15%. Transmigrated PMNs increased from
14.0 ± 3.7% to 46.0 ± 11.9% after 100 ng/ml IL-8/CXCL8
(P < 0.05); 1000 ng/ml IL-8/CXCL8 had no further effect
on migration on PMNs. Accordingly, a 90 min incubation
time and a concentration of 100 ng/ml IL-8/CXCL8 were
used for all subsequent migration assays.
IL-8/CXCL8-induced upstream kinases phosphorylation
We first demonstrated that the 100 ng/ml concentration
of IL-8/CXCL8 used in these studies caused phosphory-
lation of critical upstream kinases, ERK-1/2, p38 MAPK
and Akt/PKB (a target protein for PI3K), in the same
PMN isolates (Figure 2). Phosphorylated ERK-1/2 was
greatest at 0.5-1 min and gradually decreased thereafter.
The p38 MAPK and Akt/PKB were constitutively
expressed in unstimulated PMNs. Treatment with IL-8/
CXCL8 upregulated the phosphorylation of p38 MAPK
and Akt/PKB, which unlike ERK-1/2, was sustained for ≥
15 min. Total protein for ERK-1/2, p38 MAPK, and Akt/
PKB was stained with respective Ab to demonstrate equal
loading of samples.
Effect of IL-8/CXCL8 on [3H]AA release and LTB4 secretion
Non-stimulated PMNs released minimal amounts of AA
and undetectable amounts of LTB4. Activation with IL-8/
CXCL8 did not elicit secretion of either AA or LTB4 in
PMNs. All treated PMNs remained viable as assessed by
trypan blue exclusion dye analysis. Measurements were
performed as described in Methods section.
IL-8/CXCL8-induced gIVaPLA2 phosphorylation
Cytosolic gIVaPLA2 is a downstream target of ERK-1/2,
p38 MAPK and PI3K during cell adhesion [21,23,25]. We
next determined whether gIVaPLA2 was a downstream
regulator of PMNs in vitro. Activation of PMNs with IL-
8/CXCL8 caused rapid phosphorylation of gIVaPLA2
(Figure 3a). The phosphorylated Ser505  110-kDa-
gIVaPLA2 protein was greatest at 3 min and was sus-
tained ≥ 30 min; thereafter, the gIVaPLA2 phosphoryla-
tion decreased to baseline level. Total gIVaPLA2 proteins
stained with Ab against this protein demonstrated equal
loading of samples onto SDS-PAGE.
Immunoblotting analysis of cell-fractional components
demonstrated that gIVaPLA2 is located mainly in cyto-
plasm of unstimulated PMNs. Application of IL-8/
CXCL8 translocated the cytosolic gIVaPLA2  to some
extent, to the nuclear component of PMNs (Figure 3b).
We used FMLP as a positive control since we previously
have shown that FMLP causes the translocation of cyto-
solic gIVaPLA2 to nuclear membrane in eosinophils [33].
Inhibition of stimulated gIVaPLA2 activity
In separate studies, the inhibitory effect of TFMK and
pyrrophenone on stimulated gIVaPLA2 activity in PMNs
was determined. Baseline gIVaPLA2 activity was 41.0 ±
7.57 pmol/30 min/106 cells. Activation of PMNs with 100
ng/ml IL-8/CXCL8 increased the gIVaPLA2 activity to
Figure 2 Phosphorylation (phos) of ERK-1/2, p38 MAPK, and Akt/
PKB caused by IL-8/CXCL8. Whole cells extracts were prepared from 
isolated PMN treated with 100 ng/ml IL-8/CXCL8 at different times. Ly-
sed PMNs were then stained with specific pAb directed against phos-
phorylated a) ERK-1/2, b) p38 MAPK or c) Akt/PKB. Equal loading of 
sample is demonstrated by staining of total protein for each kinase. Re-
sults shown are representative immunoblots obtained from 4 healthy 
donors. Negative control (-con) is buffer-activated cells.
Figure 3 Phosphorylation (phos) of group IVa phospholipase A2 
(gIVaPLA2) caused by IL-8/CXCL8 activation. a) Treated PMNs were 
activated with 100 ng/ml IL-8/CXCL8 at different time intervals, in min-
utes (min) and were lysed immediately. Treated samples were subject-
ed to Western blot analysis and probed with pAb directed against 
Ser505 gIVaPLA2 (top) or pAb against total gIVaPLA2 (bottom). Total 
gIVaPLA2 protein was stained with pAb directed against total gIVaPLA2 
to indicate equal loading of samples. Representative immunoblot from 
3 independent experiments. b) Translocation of cytosolic gIVaPLA2 to 
the nuclear component of PMNs was examined by subfractionation. 
Representative blot from 3 different donors was shown after staining 
with mAb against gIVaPLA2.Meliton et al. Journal of Inflammation 2010, 7:14
http://www.journal-inflammation.com/content/7/1/14
Page 5 of 8
288.3 ± 83.6 pmol/30 min/106 cells (P < 0.001 vs baseline).
TFMK (30 μM) caused inhibition to baseline level of
gIVaPLA2 activity caused by IL-8/CXCL8 (Figure 4; P <
0.01 vs IL-8/CXCL8-activated PMNs; P = NS vs baseline).
Pyrrophenone, a potent gIVaPLA2 inhibitor, attenuated
gIVaPLA2 activity in concentration-dependent manner.
Pretreatment with 10-10 M pyrrophenone inhibited stim-
ulated gIVaPLA2 activity to 160.0 ± 20.1 pmol/30 min/106
cells (P < 0.05 vs IL-8/CXCL8 alone) and further to 67.5 ±
16.6 pmol/30 min/106 cells with 10-6 M pyrrophenone (P
< 0.01 vs IL-8/CXCL8 alone). All treated PMNs remained
viable as assessed by trypan blue exclusion dye analysis.
Blockade of IL-8/CXCL8-induced PMN migration
We next determined whether activation of gIVaPLA2 is
required for in vitro migration of PMNs. PMNs first were
co-incubated with TFMK or pyrrophenone, and migra-
tion to 100 ng/ml IL-8/CXCL8 was analyzed as % of total
PMNs in the upper chamber prior to treatment (Figure
5). TFMK (Figure 5a) or pyrrophenone (Figure 5b) atten-
uated the cell migration toward the IL-8/CXCL8 cham-
ber in concentration-dependent manner. PMN migration
caused by IL-8/CXCL8 was 53.6 ± 3.5% compared to 10.3
± 0.4% for PMNs in a buffer control chamber (P < 0.01).
Migration was attenuated to 35.7 ± 7.3% after 3 μM
TFMK (P < 0.05 vs IL-8/CXCL8 alone) and further
blocked to 29.13 ± 4.15% for cells pretreated with 30 μM
TFMK prior to IL-8/CXCL8 exposure (P < 0.01 vs IL-8/
CXCL8 alone). Treatment with 10-8  M pyrrophenone
blocked the migration to 34.1 ± 3.4% (P < 0.05 vs IL-8/
CXCL8 alone) and further to 24.9 ± 8.4% with 10-6 M pyr-
rophenone (P < 0.01 vs IL-8/CXCL8 alone). These data
demonstrate that gIVaPLA2 activation is a significant step
in neutrophil migration elicited by IL-8/CXCL8 in vitro.
Cell morphology and F-actin polymerization
We next examined the change in cell shape of migrated
PMNs co-incubated with HBSS, TFMK, or pyrrophenone
p r i o r  t o  b u f f e r  c o n t r o l  o r  I L - 8 / C X C L 8  e x p o s u r e  a t  9 0
min. Representative photomicrographs of cell morphol-
ogy are shown in Figure 6. PMNs in the buffer control
chamber retained their globular appearance after 90 min
( F i g u r e .  6 a ) .  B y  c o n t r a s t ,  P M N s  a c t i v a t e d  w i t h  I L - 8 /
CXCL8 developed an elongated cell shape with a con-
tracted tail (Figure 6b). Blockade of PMNs with TFMK
(Figure 6c) or pyrrophenone (Figure 6d) prevented the
deformability of cell shape caused by IL-8/CXCL8.
IL-8/CXCL8 caused F-actin polymerization and trans-
location of cytosolic F-actin to the inner leaflet of PMN
membrane (Figure 6). However, inhibition of gIVaPLA2,
which prevented the elongation of PMN (see Figure 6c-
d), did not block IL-8/CXCL8 -induced F-actin polymer-
Figure 4 IL-8/CXCL8-elicited gIVaPLA2 enzyme activity. PMNs 
were pretreated with either 3 μM - 30 μm arachidonyl trifluorometh-
ylketone (TFMK) or pyrrophenone for 30 min prior to IL-8/CXCL8 acti-
vation. Cytosolic gIVaPLA2 activity was expressed as picomole (pmol) 
arachidonic acid (AA)/30 min/106 cells [31]. Results are the mean ± SEM 
from N = 5 donor isolations. *P < 0.05 vs IL-8/CXCL8-activated PMNs; 
**P < 0.01 vs IL-8/CXCL8 -activated PMNs.
Figure 5 Blockade of IL-8/CXCL8-induced cell migration by 
arachidonyl trifluoromethylketone (TFMK) or pyrrophenone. 
PMNs were pretreated with 1 μM - 30 μM TFMK or 10-9 M - 10-6 M pyr-
rophenone for 30 min prior to IL-8/CXCL8 exposure. PMN migration 
was assessed by measuring the total myeloperoxidase activity in the 
neutrophil fraction (see Methods section). Data are expressed as % cell 
migration from N = 6 isolations. *P < 0.05; **P < 0.01 as indicated.Meliton et al. Journal of Inflammation 2010, 7:14
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ization (Figure 6g-6h). Thus, while activation of
gIVaPLA2 is essential for the change in shape of PMNs, F-
actin polymerization, another essential step for cell
migration, is not regulated by gIVaPLA2.
Discussion
The objective of this study was to examine the functional
role of gIVaPLA2 in the regulation of PMNs migration
caused by IL-8/CXCL8. Prior studies have reported the
signaling role of upstream kinases, ERK-1/2, p38 MAPK,
and PI3K [1,5,6], in the initiation of cell migration; how-
ever, the downstream regulation of PMN migration elic-
ited by IL-8/CXCL8 has not been elucidated previously.
We used a transwell-migration chamber [28] and deter-
mined whether inhibition of activated gIVaPLA2  by
TFMK or pyrrophenone blocked PMN migration caused
by IL-8/CXCL8. We also examined the functional role of
gIVaPLA2  in causing in PMN elongation and F-actin
polymerization, which both are necessary for PMN
migration [34,35]. While the specific mechanism causing
the PMN change in cell shape was not elucidated fully in
these studies, we found that inhibition of gIVaPLA2 is suf-
f i c i e n t  t o  b l o c k  c h a n g e  i n  c e l l  s h a p e  c a u s e d  b y  I L - 8 /
CXCL8 even in the presence of F-actin polymerization
(Figure 6).
Studies were designed using IL-8/CXCL8, a potent
chemoattractant of PMNs. Prior studies have suggested
that IL-8/CXCL8 is rather weak stimulator of human
PMNs in comparison to rodent models [36]. Activation of
PMNs with IL-8/CXCL8 did not elicit arachidonic acid or
LTB4 secretion in human PMNs. Thus, our findings sug-
gest that IL-8/CXCL8 caused transmigration of PMNs by
Figure 6 Change in cell shape and F-actin polymerization of treated PMNs. (a-d) At 90 min incubation time, migrated PMNs (N = 4 donors) were 
harvested from the IL-8/CXCL8 chamber of the transwell migration apparatus. Change in cell shape was examined by confocal microscopy. Resting 
PMNs treated with either buffer (a; baseline), 30 μM TFMK (c) or (d) 10-6 M pyrrophenone (pyrro) for 30 min prior to migration toward IL-8/CXCL8. Treat-
ed PMNs were then fixed with 10% paraformaldehyde solution and cytoslides were prepared to examine the change in cell shape. For all groups, base-
line is buffer-treated cells. Photomicrographs depict high power (630× magnification). (e-h) Representative confocal photomicrographs of F-actin 
polymerization caused by buffer (e) or IL-8/CXCL8 (f) in the presence or absence of arachidonyl trifluoromethylketone (TFMK; g) or pyrrophenone (pyr-
ro; h). For all groups, baseline is buffer-treated cells (e). Photomicrographs depict high power (630× magnification).Meliton et al. Journal of Inflammation 2010, 7:14
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a process that does not involve activation of arachidonate
synthesis.
Cytosolic gIVaPLA2 is a critical messenger protein for
cellular adhesion [21,22,27]. We have shown recently that
neutrophil or eosinophil binding to ICAM-1 is mediated
through activation of ERK-1/2 and subsequent phospho-
rylation of gIVaPLA2 [22-24,27]. In all prior cases, we
have found that stimuli that upregulate cell adhesion
CD11b expression also induce the activation of gIVaPLA2
[22,24,25,27]. However, the role of gIVaPLA2 to mediate
PMN migration has not been previously reported.
Initial experiments were performed to confirm that
upstream kinases, ERK-1/2, p38 MAPK, and PI3K, were
activated by the concentration of IL-8/CXCL8 used in
these studies (Figure 2). Immunoblotting analysis demon-
strates that IL-8/CXCL8 elicited rapid phosphorylation of
ERK-1/2, p38 MAPK, and Akt/PKB (Figure 2), confirm-
ing that these kinases were activated in these experi-
ments; however, the downstream signaling pathway for
cell migration has not been characterized. In this study,
we used two-unrelated pharmacological inhibitors of
gIVaPLA2, TFMK and pyrrophenone, to elucidate the
role of gIVaPLA2 in cell migration. Transmigration of
PMNs was blocked substantially in the presence of
upstream phosphorylation of ERK-1/2, p38 MAPK and
Akt/PKB (a target protein of PI3K) using inhibitors of
activated gIVaPLA2. Accordingly, these data indicate a
downstream regulatory role for gIVaPLA2  in  in vitro
PMN migration subsequent to activation of upstream
kinases by IL-8/CXCL8.
Immunoblotting analysis demonstrated that IL-8/
CXCL8 caused phosphorylation and translocation of
cytosolic gIVaPLA2 to the nuclear component of PMNs
[27]. It has been shown that gIVaPLA2 inhibition effec-
tively blocked cell adhesion and secreted mediators after
cell activation [21,24,31]. We have demonstrated that
inhibition of gIVaPLA2 blocked both gIVaPLA2 enzymatic
activity (Figure 4) and cell migration (Figure 5) elicited by
IL-8/CXCL8 in concentration dependent manner. These
data thus imply that activated gIVaPLA2 is an essential
intermediate step in PMN migration in vitro.
Prior studies have demonstrated that interference with
F-actin rearrangement could contribute to decrease cell
migration [37]. We observed that inhibition of gIVaPLA2
with TFMK or pyrrophenone did not prevent the rear-
rangement of F-actin assembly elicited by IL-8/CXCL8.
F-actin polymerization still was evident around the edges
of inner cell membrane (Figure 6g-h). These findings sug-
gest that while IL-8/CXCL8 caused change in cell shape,
gIVaPLA2 does not directly regulate the rearrangement of
the actin cytoskeleton in PMNs.
It is important to note some limitations to our in vitro
models of PMN migration. We used transwell chamber in
vitro to study transmigration of human PMNs. Migration
in vitro occurred in the absence of β2-integrin ligation,
which is the first step (adhesion) in cell migration in vivo
[38]. In vivo conditions are a more complex environment,
and it is not possible to extrapolate these data directly to
the human situation. Studies in vivo, however, do not
allow for stimulus isolation to specify mechanisms and
sequence of cell migration. In these studies, maximal
migration of PMNs from the upper chamber to the lower
chamber containing IL-8/CXCL8 was ~50%. This is com-
parable to other chemoattractants, i.e., FMLP, C5a and
LTB4 [39]. The initial number of cells (5 × 104 cells) was
constant in all studies, and was sufficient to cover the
area of a chamber (96-well chamber) for optimal PMN
migration.
Conclusion
Our data demonstrate that gIVaPLA2 activation caused
by IL-8/CXCL8 (subsequent to activation of upstream
kinases) may be an essential step in human PMN migra-
tion. Change in PMN cell shape and migration corre-
spond to increased activity of cytosolic gIVaPLA2 and
translocation of gIVaPLA2 to the nuclear membrane.
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